Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the viability-guided angioplasty after acute myocardial Infarction-trial (The VIAMI-trial)

Current Controlled Trials in Cardiovascular Medicine

Volumn 5, Issue , 2004, Pages

  van Loon, Ramon B ^a   Veen, Gerrit ^a   Kamp, Otto ^a   Bronzwaer, Jean G F ^a   Visser, Cees A ^a   Visser, Frans C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; DOBUTAMINE;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; ELECTIVE SURGERY; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HIGH RISK PATIENT; HUMAN; MULTICENTER STUDY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; ST SEGMENT ELEVATION; STRESS ECHOCARDIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 27544496964     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-5-11     Document Type: Article

References (47)

1. Gunnar RM, Passamani ER, Bourdillon PD, Pitt B, Dixon DW, Rapaport E, Fuster V, Reeves TJ, Karp RB, Russell ROJ: Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990, 16:249-292.
2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato P, Pearle DL, Sloan MA, Smith SCJ, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004, 44:E1-E211.
3. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13-20.
4. Van de WF, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W: Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003, 24:28-66.
5. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002, 23:1190-1201.
6. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E: Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001, 286:1356-1359.
7. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990, 336:65-71.
8. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992, 339:753-770.
9. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993, 329:1615-1622.
10. Meijer A, Verneugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ: Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 1993, 87:1524-1530.
11. Veen G, Meyer A, Verheugt FW, Werter CJ, de Swart H, Lie KI, van der Pol JM, Michels HR, van Eenige MJ: Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. J Am Coll Cardiol 1993, 22:1755-1762.
12. Meijer A, Verheugt FW, van Eenige MJ, Werter CJ: Left ventricular function at 3 months after successful thrombolysis. Impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling. Circulation 1994, 90:1706-1714.
13. Nijland F, Kamp O, Verheugt FW, Veen G, Visser CA: Long-term implications of reocclusion on left ventricular size and function after successful thrombolysis for first anterior myocardial infarction. Circulation 1997, 95:111-117.
14. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989, 320:618-627.
15. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. BMJ 1991, 302:555-560.
16. Erbel R, Pop T, Henrichs KJ, von Olshausen K, Schuster CJ, Rupprecht HJ, Steuernagel C, Meyer J: Percutaneous transluminal coronary angioplasty after thrombolytic therapy: a prospective controlled randomized trial. J Am Coll Cardiol 1986, 8:485-495.
17. Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE,.: A randomized trial of intrevenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987, 317:1613-1618.
18. Rogers WJ, Baim DS, Gore JM, Brown BG, Roberts R, Williams DO, Chesebro JH, Babb JD, Sheehan FH, Wackers FJ,.: Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation 1990, 81:1457-1476.
19. Simoons ML, Arnold AE, Betriu A, de Bono DP, Col J, Dougherty FC, von Essen R, Lambertz H, Lubsen J, Meier B,.: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988, 1:197-203.
20. Topol EJ, Califi RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW: A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987, 317:581-588.
21. Froelicher VF, Perdue S, Pewen W, Risch M: Application of meta-analysis using an electronic spread sheet to exercise testing in patients after myocardial infarction. Am J Med 1987, 83:1045-1054
22. Basu S, Senior R, Raval U, Lahiri A: Superiority of nitrate-enhanced 201TI over conventional redistribution 201TI imaging for prognostic evaluation after myocardial infarction and thrombolysis [see comments]. Circulation 1997, 96:2932-2937.
23. Bigi R, Desideri A, Bax JJ, Galati A, Coletta C, Fiorentini C, Fioretti PM: Prognostic interaction between viability and residual myocardial schemia by dobutamine stress echocardiography in patients with acute myocardial infarction and mildly impaired left ventricular function. Am J Cardiol 2001, 87:283-288.
24. Huitink JM, Visser FC, Bax JJ, van Lingen A, Groenveld AB, Teule GJ, Visser CA: Predictive value of planar 18F-fluorodeoxyglucose imaging for cardiac events in patients after acute myocardial infarction. Am J Cardiol 1998, 81:1072-1077.
25. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, Sapp SK, MacIntyre WJ, Thomas JD. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994, 90:2687-2694.
26. Marzullo POVIPWGNCMRIESC, CNR Institute of Clinical Physiology PI: Viability Impact on Prognosis (VIP): Results in 622 patients. J Am Coll Cardiol 1998, 31:167-167.
27. Nijland F, Kamp O, Verhorst PM, de Voogt WG, Visser CA: In-hospital and long-term prognostic value of viable myocardium detected by dobutamine echocardiography early after acute myocardial intarction and its relation to indicators of left ventricular systolic dysfunction. Am J Cardiol 2001, 88:949-955.
28. Petretta M, Cuocolo A, Bonaduce D, Nicolai E, Cardei S, Berardino S, Iannicello A, Apicella C, Bianchi V, Salvatore M: Incremental prognostic value of thallium reinjection after stress- redistribution imaging in patients with previous myocardial infarction and left ventricular dysfunction. J Nucl Med 1997, 38:195-200.
29. Previtali M, Fetiveau R, Lanzarini L, Cavalotti C, Klersy C: Prognostic value of myocardial viability and ischemia detected by dobutamine stress echocardiography early after acute myocardial infarction treated with thrombolysis. J Am Coll Cardiol 1998, 32:380-386.
30. Salustri A, Ciavatti M, Seccareccia F, Palamara A: Prediction of cardiac events after uncomplicated acute myocardial infarction by clinical variables and dobutamine stress test. J Am Coll Cardiol 1999, 34:435-440.
31. Sicari R, Picano E, Landi P, Pingitore A, Bigi R, Coletta C, Heyman J, Casazza F, Previtali M, Mathias WJ, Dodi C, Minardi G, Lowenstein J, Garyfallidis X, Cortigiani L, Morales MA, Raciti M: Prognostic value of dobutamine-atropine stress echocardiography early after acute myocardial infarction. Echo Dobutamine International Cooperative (EDIC) Study. J Am Coll Cardiol 1997, 29:254-260.
32. Iskander S, Iskandrian AE: Prognostic utility of myocardial viability assessment. Am J Cardiol 1999, 83:696-702, A7.
33. Carlos ME, Smart SC, Wynsen JC, Sagar KB: Dobutamine stress echocardiography for risk stratification after myocardial infarction [see comments]. Circulation 1997, 95:1402-1410.
34. Picano E, Sicari R, Landi P, Cortigiani L, Bigi R, Coletta C, Galati A, Heyman J, Mattioli R, Previtali M, Mathias WJ, Dodi C, Minardi C, Lowenstein J, Seveso G, Pingitore A, Salustri A, Raciti M: Prognostic value of myocardial viability in medically treated patients with global left ventricular dysfunction early after an acute uncomplicated myocardial infarction: a dobutamine stress echocardiographic study. Circulation 1998, 98:1078-1084.
35. Samad BA, Frick M, Hojer J, Urstad MJ: Early low-dose dobutamine echocardiography predicts late functional recovery after thrombolyzed acute myocardial infarction. Am Heart J 1999, 137:489-493.
36. Yoshida K, Gould KL: Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol 1993, 22:984-997.
37. Nijland F, Kamp O, Verhorst PM, de Voogt WG, Bosch HG, Visser CA: Myocardial viability: impact on left ventricular dilatation after acute myocardial infarction. Heart 2002, 87:17-22.
38. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM: Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: Comparison of pooled data. Journal of the American College of Cardiology 1997, 30:1451-1460.
39. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997, 336:1689-1696.
40. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998, 352:87-92.
41. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001, 344:1895-1903.
42. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolaviclus S, Copland I, Fox KA: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
43. Steinhubl SR, Berger PB, Mann JTIII, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
44. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Beli WR, Knatterud G, Robertson TL, Terrin ML: Thrombolysis in Myocardial-Infarction (Timi) Trial - Phase-I - Hemorrhagic Manifestations and Changes in Plasma-Fibrinogen and the Fibrinolytic System in Patients Treated with Recombinant Tissue Plasminogen-Activator and Streptokinase. Journal of the American College of Cardiology 1988, 11:1-11.
45. Poldermans D, Sozzi FB, Bax JJ, Boersma E, Duncker DJ, Vourvouri E, Elhendy A, Valkema R, Roelandt JR: Influence of continuation of beta blockers during dobutamine stress echocardiography for the assessment of myocardial viability in patients with severe ischemic left ventricular dysfunction. Am J Cardiol 2001, 88:68-70.
46. Weissman NJ, Levangie MW, Newell JB, Guerrero JL, Weyman AE, Picard MH: Effect of beta-adrenergic receptor blockade on the physiologic response to dobutamine stress echocardiography. Am Heart J 1995, 130:248-253.
47. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I,.: Recommendations for quantitation of the left ventricle by two-dimensional, echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.